Dr. Stanley Liauw serves as the Director of Clinical Operations and is the clinical lead for the genitourinary (GU) cancer program and the gastrointestinal (GI) cancer program within the Department of Radiation and Cellular Oncology at the University of Chicago. In the past 10 years on faculty, Dr. Liauw has developed research programs in these disease sites, with an interest in outcomes research and clinical trials. The central mission of his research is to conduct clinical studies to define current clinical outcomes and areas of need, develop hypotheses, and test novel regimens to reduce the morbidity or mortality of radiation therapy in the treatment of cancer.
A major focus of Dr. Liauw's efforts include the periodic analysis and reporting of cancer outcomes with radiation therapy. This work, derived from multiple institutional databases of more than 2000 patients, has resulted in numerous abstract presentations and publications in peer-reviewed journals such as Journal of Clinical Oncology, International Journal of Radiation Oncology, Biology, Physics and Cancer. These contributions generally fall into 3 categories of interest: presenting hypotheses to improve the therapeutic ratio of therapy, studying the use of imaging in radiation oncology, and exploring potential markers of response to therapy.
A number of clinical protocols have been opened for patients with genitourinary and gastrointestinal cancers. Dr. Liauw has investigated and initiated trials for a: phase I study of dose escalated stereotactic body RT trial for unresectable pancreatic cancer, phase II quality of life study of oral hormonal therapy with RT for prostate cancer, phase I study for oligometastatic renal cell cancer, and phase I randomized study for hepatocellular carcinoma treated with RT and immunotherapy.
Outside of his research interests, Dr. Liauw has overseen several intradepartmental projects aimed at improving clinical workflow and patient safety, with potential downstream effects on patient and employee satisfaction. He served as the clinical lead for the implementation of intraoperative radiation therapy in 2015, as an Associate Editor for GI cancers for the International Journal of Radiation Oncology, Biology, and Physics, as an examiner and question writer for the American Board of Radiology for GU cancers, and an invited speaker for national and international educational lectures such as through the American Society of Radiation Oncology (ASTRO) and the American Urological Association. He has been an invited Visiting Professor for resident education at multiple institutions, and has been regularly recognized from the University of Chicago training program as a top educator. He has been an ad hoc reviewer of manuscripts for more than 20 scientific journals, including Journal of Clinical Oncology and the New England Journal of Medicine.
University of Florida
Gainesville, FL
Residency - Radiation Oncology
2006
Brigham and Women's Hospital
Boston, MA
Internship - Internal Medicine
2002
UT Southwestern Medical School
Dallas, TX
MD - Medicine
2001
MIT
Cambridge, MA
BS - Chemical Engineering
1997
Bladder-Preserving Trimodality Therapy With Capecitabine.
Bladder-Preserving Trimodality Therapy With Capecitabine. Clin Genitourin Cancer. 2024 04; 22(2):476-482.e1.
PMID: 38228414
Multidisciplinary Collaboration is Key.
Multidisciplinary Collaboration is Key. Int J Radiat Oncol Biol Phys. 2023 Dec 01; 117(5):1047-1048.
PMID: 37980133
Monitoring Intrafraction Motion of the Prostate During Radiation Therapy: Suggested Practice Points From a Focused Review.
Monitoring Intrafraction Motion of the Prostate During Radiation Therapy: Suggested Practice Points From a Focused Review. Pract Radiat Oncol. 2024 Mar-Apr; 14(2):146-153.
PMID: 37875222
A Contemporary Report of Low-Dose-Rate Brachytherapy for Prostate Cancer Using MRI for Risk Stratification: Disease Outcomes and Patient-Reported Quality of Life.
A Contemporary Report of Low-Dose-Rate Brachytherapy for Prostate Cancer Using MRI for Risk Stratification: Disease Outcomes and Patient-Reported Quality of Life. Cancers (Basel). 2023 Feb 20; 15(4).
PMID: 36831677
ASO Visual Abstract: Intraoperative Radiation Therapy for Colorectal or Anal Cancer at Risk for Margin-Positive Resection: Initial Results of a Single-Institution Registry.
ASO Visual Abstract: Intraoperative Radiation Therapy for Colorectal or Anal Cancer at Risk for Margin-Positive Resection: Initial Results of a Single-Institution Registry. Ann Surg Oncol. 2023 Jan; 30(1):333-334.
PMID: 36224512
Multidisciplinary Management and Radiotherapy Recommendations for Clinically and Pathologically Node-positive Bladder Cancer.
Multidisciplinary Management and Radiotherapy Recommendations for Clinically and Pathologically Node-positive Bladder Cancer. Semin Radiat Oncol. 2023 Jan; 33(1):35-50.
PMID: 36517192
ASO Visual Abstract: Phase II Prospective Open-Label Randomized Controlled Trial Comparing Standard of Care Chemotherapy with and without Sequential Cytoreductive Interventions for Patients with Oligometastatic Foregut Adenocarcinoma and Undetectable Circulating Tumor-Deoxyribose Nucleic Acid (ctDNA) Levels.
ASO Visual Abstract: Phase II Prospective Open-Label Randomized Controlled Trial Comparing Standard of Care Chemotherapy with and without Sequential Cytoreductive Interventions for Patients with Oligometastatic Foregut Adenocarcinoma and Undetectable Circulating Tumor-Deoxyribose Nucleic Acid (ctDNA) Levels. Ann Surg Oncol. 2022 Dec; 29(Suppl 3):616-617.
PMID: 35930113
Phase II Randomized Study of Salvage Radiation Therapy Plus Enzalutamide or Placebo for High-Risk Prostate-Specific Antigen Recurrent Prostate Cancer After Radical Prostatectomy: The SALV-ENZA Trial.
Phase II Randomized Study of Salvage Radiation Therapy Plus Enzalutamide or Placebo for High-Risk Prostate-Specific Antigen Recurrent Prostate Cancer After Radical Prostatectomy: The SALV-ENZA Trial. J Clin Oncol. 2023 02 20; 41(6):1307-1317.
PMID: 36367998
Intra-operative Radiation Therapy for Colorectal or Anal Cancer at Risk for Margin-Positive Resection: Initial Results of a Single-Institution Registry.
Intra-operative Radiation Therapy for Colorectal or Anal Cancer at Risk for Margin-Positive Resection: Initial Results of a Single-Institution Registry. Ann Surg Oncol. 2022 Oct 18.
PMID: 36255512
ASO Visual Abstract: Intraoperative Radiation Therapy for Colorectal or Anal Cancer at Risk for Margin-Positive Resection: Initial Results of a Single-Institution Registry.
ASO Visual Abstract: Intraoperative Radiation Therapy for Colorectal or Anal Cancer at Risk for Margin-Positive Resection: Initial Results of a Single-Institution Registry. Ann Surg Oncol. 2022 Oct 12.
PMID: 36224512